Fly Play hf.: Fly Play hf: 110m USD in sales in Q3, EBIT grew tenfold from last year and a net profit of 5.2m USD
Fly Play hf: 110m USD in sales in Q3, EBIT grew tenfold from last year and a net profit of 5.2m USD
● PLAY airlines turned a USD 5.2 million profit in the 3rd quarter of 2023 compared to net loss of USD 2.9 million in Q3 2022.
● Total revenue in Q3 in 2023 increased 84% compared to Q3 2022. Revenues grew from USD 59.9 million in Q3 2022 to USD 110.2 million in Q3 2023.
● Earnings before interest and taxes (EBIT) in Q3 increased almost tenfold from USD 1.3 million in Q3 2022 to USD 12.9 million in Q3 in 2023.
● The third quarter showed ongoing growth in ancillary revenue with 150% growth year-to-date compared to 2022. Ancillary yields per passenger have grown 35% year on year.
● In Q3, PLAY broke its previous record for number of passengers carried in one month in July with 191,577 thousand passengers and a load factor of 91.1%.
● PLAY operated flights to 33 destinations in the quarter with an on-time performance of 85.1% and a load factor of 88.4%.
● RASK (Revenue per available seat kilometer) grew by 9% year-on-year and was 6.1 US cents in Q3 2023.
● Ex-Fuel CASK was 3.4 US cents in Q3 2023. Total CASK decreased by 2% year-on-year and was 5.3 US cents.
● Cash at the end of the third quarter amounted to USD 39.2 million including restricted cash. The company has no external interest-bearing debt.
● Forward RASK (Revenue per available seat kilometer) is tracking ahead of last year and forward booking status is strong despite 79% capacity increase in Q1 2024.
Birgir Jónsson, CEO:
We are all very proud of our financial and operational results for the third quarter and especially of the fact that PLAY generated a net profit of 5.2 million USD, the first-ever quarterly net profit since our inaugural flight in June 2021. Operational profit grew tenfold from the same quarter last year, revenues were up 84%, and passenger numbers increased by 74%, quite remarkable facts and a testament to a well-performing business model and a great team of professionals.
PLAY has been on a very steep growth trajectory as we have been increasing our fleet size, expanding our network, and welcoming many new Players to our team. Growth is expensive, and it is, therefore, a notable achievement that we have been able to increase our unit revenues and grow our ancillary revenues at the same time, resulting in a strong net profit and a healthy cash position. We do not plan to grow as much next year but will focus on optimizing and stabilizing our operation and increasing our profitability before we commence our next growth phase in 2025, which will see more aircraft, some of whom have already been secured, and a more extensive and denser network. We continue to have a laser focus on our cost base, and our team has been successful in maintaining a very competitive unit cost, something that is absolutely critical for our success but nonetheless a real challenge in today's inflationary business environment. I sincerely want to thank all the exceptional individuals who make up the PLAY team for their fantastic work, and I am absolutely convinced that nothing can stand in their way in the future as they continue to play to win!
|Operating statistics||Q3 2023||Q3 2022||Change|
|Number of flights||no.||3,222||1,994||1,228|
|Number of operating destinations||no.||33||22||11|
|Number of aircraft in operation||no.||10||6||4|
|Percentage of arrivals on time (OTP)||%||85%||85%||0.1 ppt|
|Number of passengers||000s||540||311||74%|
|Available seat kilometers (ASK)||mill||1,821||1,067||71%|
|Revenue passenger kilometers (RPK)||mill||1,611||913||76%|
|Stage length (km)||no.||2,941||2,918||1%|
|Load factor||%||88%||85%||3 ppt|
|Operating revenue||USD mill||110.2||59.9||50.3|
|Operating expenses||USD mill||82.1||49.3||32.8|
|EBIT margin||%||12%||2%||10 ppt|
|Net operating results||USD mill||5.2||-2.9||8.1|
|Total assets||USD mill||493.8||327.6||166.3|
|Total liabilities||USD mill||468.4||287.9||180.4|
|Total shareholders equity||USD mill||25.5||39.6||-14.2|
|Cash and cash equivalents (incl. restricted)||USD mill||39.2||29.6||9.6|
|Share price at period-end||Per share||8.8||16.3||-|
|Earnings per share||US cents||0.80||-0.50||-|
|Airfare per passenger||USD||144||150||-4%|
|Ancillary per passenger||USD||58||43||34%|
|Yield per passenger||USD||201||193||4%|
|CASK (incl. Fuel & emissions)||US cents||5.3||5.5||-2%|
|CASK (excl. Fuel & emissions)||US cents||3.4||3.1||11%|
|CO₂ per RPK (grams CO₂ per RPK)||no.||56.9||62.3||-9%|
|CO₂ emissions in tons from jet fuel||no.||91,578||56,960||61%|
Higher revenues and higher load factor despite significant increase in capacity
During Q3 2023, PLAY operated flights to 33 destinations in Europe and North America. Capacity measured in available seat kilometers (ASK) increased by 71% compared to Q3 2022. Load factor improved by 3.4 percentage points from 85% in Q3 2022 to 88.4% in Q3 2023. In Q3 2023, PLAY flew 540 thousand passengers which is 74% more than the number of passengers flown in Q3 2022, when PLAY flew 311 thousand passengers.
Despite a 70% increase in capacity, revenue increased 84% and unit revenue (RASK) increased 9%. The year-on-year improvement in load factor and unit revenue is a testament of how well-established PLAY is becoming in our key markets.
In Q3 2023, 24% of total passengers flown were traveling from Iceland, 33% to Iceland and 43% were connecting passengers (VIA). Via traffic increased by 4 percentage points year-on-year. The load factor on routes to/from North America was 92% during the quarter. Number of passengers flown increased by 74% year on year, with an 88% increase in passengers flying to and from North America and a 66% increase in passengers to and from Europe.
The increase in VIA traffic, both in terms of number of passengers as well as share of total traffic, compared to Q3 2022, was driven by increased connectivity within the network, greater awareness of PLAY in foreign markets and strong U.S. consumer demand. All these factors, plus the launch of bundled fares in February, resulted in improved yields from VIA passengers compared to Q3 2022.
PLAY continued to deliver a strong operational performance with 85.1% of flights arriving on time in Q3 2023, which is a significantly better performance compared to the airline’s main competitors. This is a testament to the incredible work of the entire team at PLAY and service partners.
Q3 2023 financial results
After a significant ramp-up phase in the past quarters, adding 4 aircraft and 13 destinations, the third quarter of 2023 was PLAY’s most successful financial quarter in its history.
Net profit for the quarter amounted to 5.2 million, a turnaround of USD 8.1 million from last year when the net loss was USD 2.9 million. Revenues for Q3 2023 were USD 110.2 million compared to USD 59.9 million in Q3 2022. PLAY’s total revenue per available seat kilometer (TRASK) in Q2 2023 increased by 9% compared to Q3 2022 and was 6.1 US cents. EBIT was positive in Q2 2023 in the amount of USD 12.9 million, compared to USD 1.3 million for the same period last year.
PLAY has placed significant emphasis on increasing ancillary revenue with improved product offerings such as bundled fares which launched in February and other additional ancillary products. Ancillary yield per passenger in Q3 2023 was USD 58 and increased by 35% compared to Q3 2022 when it was USD 43. Total ancillary revenue this year to date is 150% higher than at the same time 2022.
Total operating expenses, including depreciation, amounted to USD 82.1 million in the quarter resulting in unit cost per available seat kilometer (CASK) of 5.3 US cents which decreased by 2% compared to the same period last year. Ex-Fuel CASK was 3.4 US cents and increased 11% year-on-year due to inflation and one-off maintenance items. PLAY expects its Ex-Fuel CASK to be around 3.7 USD cents for the full year.
Financial income and expenses were negative in the quarter in the amount of USD 6 million, thereof, USD 4.6 million was due to interest expenses of lease liabilities.
PLAY’s total assets amounted to USD 493.8 million at the end of the period compared to USD 331.5 million at year-end 2022. The company operated ten aircraft for the whole period. Trade and other receivables amounted to USD 27.9 million and comprised mostly of acquirer’s unpaid ticket sales. Deferred income decreased during the period and was USD 40.7 million at the end of September compared to USD 82.4 million at the end of June, this is expected due to seasonality. Unwinding of working capital position during the third quarter, due to seasonality, resulted in decreased cash from Q2. At period-end, the company’s cash position was USD 39.2 million, including restricted cash. Total equity at period-end was USD 25.5 million. The company has no external interest-bearing debt.
Best crew and new ancillary products
USA Today´s 10Best announced that PLAY´s crew has been voted #1 by its readers. PLAY earned its nomination from USA Today and 10Best, and following a four-week voting period with input from readers and fans, PLAY emerged as the top choice for cabin crew excellence. PLAY has been operating flights from 2021 and only started flights in North America in 2022. To win this award after being nominated along with some of the world’s best-known airlines is a true achievement for PLAY and this recognition is a testament to the outstanding efforts of our dedicated cabin crew team and a tremendous honor for our young airline.
PLAY has been introducing a digital onboard passenger self service via passengers’ own personal devices on selected aircraft. Passengers can order their food and beverages from their seat using their own device. Early test results from onboard trials indicate increased sales on PLAY flights. The solution offers dynamic pricing capabilities and rapid changing product offering possibilities. Passengers can also follow their route progress and view a live map as well as enjoy free video games and family-friendly entertainment.
Additionally, PLAY has introduced Space seats which are aisle or window seats with more legroom on selected flights at the front of the plane without a neighbor. The middle seat is blocked with a comfortable side table. This reduces capacity in low season to 200 seats per Airbus A321neo aircraft instead of 214 seats and therefore reduces labor cost as fewer crew members are needed. The product increases ancillary revenue and is easy to remove when seasonal demand returns.
PLAY’s outlook for the full year is unchanged from the end-of-summer information meeting at the end of September. The outlook anticipates carrying around 1.5 million passengers in 2023 and EBIT will be around negative USD 10 million. The airline is projected to generate a total revenue of around USD 280 million in 2023.
Investor presentation webcast, October 26, 2023
CEO Birgir Jónsson and CFO Ólafur Þór Jóhannesson will present the company’s results on Thursday, October 26, at 4:15 p.m. (GMT). The presentation will be streamed in English via webcast: https://www.flyplay.com/financial-reports-and-presentations.
• Q4 and Financial Statements 2023 - 8 February 2024
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t